|
Synonyms: 1E10 | Vaxira®
racotumomab is an approved drug (Cuba and Argentina (2013))
Compound class:
Antibody
Comment: Racotumomab is an anti-idiotype therapeutic cancer vaccine directed against the ganglioside N-glycolil (NGc) GM3 [2,5], which has been identified on the cell surface of malignant cells from lung [4] and breast tumours [8], melanoma [10-11], and neuroectodermal pediatric tumours [6-7,12-13]. Racotumomab is being investigated for its antineoplastic activity.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (Cuba and Argentina (2013)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 8998 | racotumomab |
| Synonyms |
| 1E10 | Vaxira® |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 225 |
| Other databases | |
| GtoPdb PubChem SID | 249565675 |
| Search PubMed clinical trials | racotumomab |
| Search PubMed titles | racotumomab |
| Search PubMed titles/abstracts | racotumomab |
| Wikipedia | Racotumomab |
